Rafaela Quintero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rafaela Quintero has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Birgit C Schultes
Advanced Immune Therapeutics, Inc, Charlestown, MA, USA
1 shared publication - Christopher F Nicodemus
AIT Strategies, POB 429 Sunset Lane, Franconia, NH 03580, USA
1 shared publication - Elizabeth Ortiz-Sánchez
Subdirection of Basic Research, National Cancer Institute of Mexico (Instituto Nacional de Cancerología, INCan) 4 , Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, Mexico City 14080
1 shared publication - Gustavo Helguera
Instituto de Biología y Medicina Experimental (IBYME-CONICET)
1 shared publication - Jose Rodriguez
Department of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California, Los Angeles, California, 90095, USA
1 shared publication - Maggie Kozman
Departments of Internal Medicine
1 shared publication
Latest Publications
- Open Access
- 17 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.
- 17 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
Open AccessA novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.